Source: CureToday articles
TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the phase 2b SunRISe-1 study.
Recent Content
- Asembia AXS25: Cell and Gene Therapies Enter New Phase of Growth in Specialty Pharmacy
- Asembia AXS25: Pharmacists Continue to Expand Clinical, Collaborative Role in Health Care
- Asembia AXS25: Navigating Challenges in Cell and Gene Therapy
- Targeted Therapies Transform CLL Care: Inside the Era of BTK and BCL-2 Inhibitors
- Asembia AXS25: Pharmacy Perspectives on the Inflation Reduction Act
- An AI-Driven Companion Diagnostic Receives FDA Designation in NSCLC
- AACR 2025: Orally Bioavailable RIPTAC Therapeutic Targets p53-Y220C Mutant Tumors for Selective Cancer Cell Death
- Investigating the Addition of Surgery to ICI Therapy in Kidney Cancer
- Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
- TAR-200 Shows High Response Rates in Bladder Cancer Subset